Clinical Trial Update: A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update of epoetin beta (NeoRecormon) in cancer patients with anemia (solid tumors or hematologic malignancies) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• NeoRecormon (epoetin beta)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 4 | Status: COMPLETED